drugset / Trial / NCT06692426
Trial of Cell Based Therapy for DMD
Phase 1
Recruiting
8 enrolled
Masonic Cancer Center, University of Minnesota
Duchenne UK · collabParent Project Muscular Dystrophy · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD)
Timeline
- Start
- 2025-03-20
- Primary completion
- 2027-03-03
- Completion
- 2027-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MyoPAXon | Cell therapy | 2.5e+07 cells | Intramuscular |
| Subject | MyoPAXon | Cell therapy | 5e+07 cells | Intramuscular |
| Subject | MyoPAXon | Cell therapy | 1e+08 cells | Intramuscular |
| Subject | MyoPAXon | Cell therapy | 2e+08 cells | Intramuscular |
| Background | Tacrolimus | Small molecule | — | — |